Walleye Capital
AVXL icon

Walleye Capital’s Anavex Life Sciences AVXL Stock Holding History

Walleye Capital’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22K Sell
398
-5,611
-93% -$24.3K ﹤0.01% 4257
2025
Q4 		$21.4K Buy
+6,009
New +$36.8K ﹤0.01% 4239

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Walleye Capital's AVXL Position: Q1 2026 in Review

Walleye Capital reduced its Anavex Life Sciences (AVXL) stake by 93% in Q1 2026, selling an estimated $24.3K and leaving 398 shares worth $1.22K. The position accounts for ﹤0.01% of the portfolio, ranked #4257.

Walleye Capital first reported a position in AVXL in Q4 2025 and has held it in 2 quarters since. The position peaked at $21.4K in Q4 2025. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • Walleye Capital held 398 shares of Anavex Life Sciences worth $1.22K as of Q1 2026.
  • Walleye Capital sold 5,611 Anavex Life Sciences shares in Q1 2026, an estimated $24.3K.
  • Anavex Life Sciences made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #4257 holding.
  • Walleye Capital first reported a position in Anavex Life Sciences in Q4 2025 and has held it in 2 quarters since.
  • Walleye Capital's Anavex Life Sciences position peaked at $21.4K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.